EGFR and cervical cancer: The vascular endothelial growth factor (VEGF) and the epidermal growth factor receptor (EGFR) is the most commonly selected proangiogenic factors for anti-angiogenic therapy, and the US Food and Drug Administration (FDA) has approved an anti-VEGF targeted therapy in combination with chemotherapy for patients with metastatic, persistent, or recurrent cervical cancer, and several targeted therapies are still investigated [5,6].